Endo, NuPathe, Teva deal

NuPathe said that Teva made an unsolicited cash offer to acquire the specialty pharma for $3.65 per share in cash up front, or about $114.4 million, based on

Read the full 280 word article

How to gain access

Continue reading with a
two-week free trial.